Simple regimen needed for HCV

Combining sofosbuvir and velpatasvir offers “a simple, effective regimen for the treatment of chronic hepatitis C” (HCV) infection, according to new ‘real world’ research presented during the International Liver Congress in Vienna recently.

The study, which included 5,541 patients, found that 12 weeks’ treatment with sofosbuvir and velpatasvir in a single tablet produced sustained virological response rates of 92.7 and 98.5 per cent in the intention-to-treat and per-protocol analyses respectively. The combination was “highly” effective regardless of genotype, fibrosis stage, treatment history and patient characteristics.

Simplicity is key in reaching the WHO goals for HCV elimination by 2030, the authors conclude. Twelve weeks’ treatment with sofosbuvir and velpatasvir “is a simple and highly effective regimen that cures HCV patients, irrespective of [genotype], cirrhosis status or treatment history, with a manageable drug interaction profile, which will contribute to the implementation of test and treat strategies”. The study was sponsored by Gilead.

Comments (0)

This website is for healthcare professionals, people who work in pharmacy and pharmacy students. By clicking into any content, you confirm this describes you and that you agree to Pharmacy Network News's Terms of Use and Privacy Policy.

We use essential, performance, functional and advertising cookies to give you a better web experience. Find out how to manage these cookies here. We also use Interest Based Advertising Cookies to display relevant advertisements on this and other websites based on your viewing behaviour. By clicking "Accept" you agree to the use of these Cookies and our Cookie Policy.